Infectious Disease
Hypersensitivity Pneumonitis
5
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Hypersensitivity Pneumonitis is an early-stage landscape with 5 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., GSK, Pfizer. 3 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 21
Phase 3
No programs
Analysis
Trial Status
8
clinical trials
Unknown status3 · 38%
Completed2 · 25%
Not yet recruiting2 · 25%
Terminated1 · 13%
Clinical Trials
Trial Activity
8 trials
Hypersensitivity Pneumonitis of Domestic Origin
Not yet recruiting·—·N/A·NCT05704218·500 enrolled
Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
Terminated·—·Phase 2·NCT02958917·40 enrolled
An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT05626387·144 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)